Ann: Cohort 3 Pharmacokinetics in MND Patients Completed, page-43

Agree 110% that the NfL data will be significant.

If one current available Treatment that has been granted FDA approval was on "Humanised Mouse Trial Data" then PAA should be streaks ahead with a Phase I/II Human Trial loaded with positive data and MPL has a 25 year safety History in Humans,, then wouldn't it be prudent for PAA to immediately apply for Orphan Drug Status upon delivering Positive results with MPL in the current MND Trial?

Plus by explaining to the Market that they will be applying for FDA Orphan Drug Status , Investors are aware this is a regulated 90 day application Process.

I'm over on BOT and they are up over 110% whilst traveling through the FDA Process now, I myself target these type of short term gains.. Just the Headline alone usually kicks the SP upward 20% / 30%, its a known inflection point , plus it focuses the markets attention directly to the current Phase I/II we are in..

Best of Luck to all Holders 79 days left to get the Oppies in the Money..NZT